just Scottie
1 day ago
$ALLR THESE PARTS OF THE LAST PR STAND OUT TO ME. TELLS ME THEY ARE ACTIVELY LOOKING FOR PARTNERS OR BUYOUT. THEY HAVE GOTTEN VERY GOOD RESULTS, SO GOOD THEY STOPPED THE LAST TRIAL EARLY. YOU DONโT DO THAT UNLESS THE PATIENTS HAVE BENIFITTED. FDA COULD COME I AND FAST FRACK THIS. ITS JUST MEANT TO EXTEND LIFE ON ADVANCED OVARIAN CANCER PATIENTS. SOFAR THEY HAVE PROVED IT SHRINKS TUMOR SIZE.
โNot only does the safety profile stand out when compared to chemotherapies, which is often the alternative for this patient group, but the safety metrics are indeed also favorable when compared to first-generation PARP inhibitors. As we see it, stenoparib may represent the next-generation alternative for advanced ovarian cancer patients. Therefore, we are aggressively working with Dr. Moore and other leading experts to design a trial that will help advance and quicken stenoparibโs clinical progress toward registration with the FDA.โ
โAfter conducting a detailed review of the stenoparib monotherapy trial data, including the data announced today, the Company has concluded that these data may be of significant interest among key oncologists, potential commercial partners, and other relevant stakeholders and therefore warrant presentation within a high-level scientific conference. Further release of these clinical data is intended to be staged to comply with the common rules of scientific conferences, which do not allow data to be published before the event.โ
The PARP inhibitor market is expected to reach $22 billion in revenue by 2028, and has historically seen significant partnerships and acquisitions.
For example, one significant acquisition included a multi-asset deal potentially totaling $1.5 billion, which featured an advanced PARP inhibitor.
Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
gdog
3 weeks ago
Multiple patients have now exceeded 30 weeks on treatment
Boston ( June 25 , 2024)โAllarity Therapeutics, Inc. (โAllarityโ or the โCompanyโ) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that multiple patients in its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have been on treatment for more than 30 weeks.
The continued durability of clinical benefit further bolsters the Companyโs announcement in early May 2024 that stenoparib had shown clear clinical benefit, including significant tumor shrinkage and long-term disease stability, in patients who had been heavily pre-treated for their ovarian cancer and otherwise have limited life expectancy. These results provided clinical proof of concept for stenoparib as a treatment in this patient population, prompting the company to halt patient enrollment to focus its resources on developing a follow-on trial designed to accelerate the path for stenoparib toward regulatory approval.
Kathleen N. Moore , MD, MS, Deputy Director of the Stephenson Cancer Center , Professor of the Section of Gynecol
gdog
3 weeks ago
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Allarity Therapeutics, Inc.
Tue, May 7, 20243 min read
In This Article:
ALLR
-26.91%
Allarity Therapeutics, Inc.Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc.
- Conversions Eliminate All Variable Priced Derivative Securities
- Conversions Eliminate Any Market Overhang from Warrants
- Series A Preferred and Warrant Conversions were Investor Initiated
- Limited Number of Warrants Convertible at $20 Per Share Remain
- Company Has Paid Off All Bridge Notes in Full
Boston (May 7, 2024)โAllarity Therapeutics, Inc. (โAllarityโ or the โCompanyโ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its capital structure has been simplified. This was achieved by the recent investor-initiated conversion of all outstanding Series A Preferred Stock into common stock, resulting in a single class of shares outstanding, and the conversion of 93% of the Companyโs outstanding warrants, including all variable-priced warrants. Following this reduction, the Company reports that only a limited number of warrants remain unexercised, specifically 256,667 warrants, each with a fixed exercise price of $20 per share. Furthermore, the Company informs that it has fully paid off all bridge notes, totaling $1,746,630, including principal and accrued interest.
Thomas Jensen, CEO of Allarity Therapeutics, stated, โThe successful conversion of these securities by our investors is a key milestone, as it streamlines our financial architecture and may enhance the attractiveness of our stock. Understanding the investment case for biotech companies like ours can be complex for investors at all levels. Therefore, we are very pleased with this development, as it allows us to focus more on sharing information about our lead asset, stenoparib, and less on explaining the intricacies of our capital structure going forward.โ
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.